AKRO - Akero Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.40
DETAILS
HIGH:
$56.00
LOW:
$38.00
MEDIAN:
$54.00
CONSENSUS:
$48.40
DOWNSIDE:
11.44%
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0.2 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | (0.2) | 0 | 0 | 0 |
| Operating Expenses | ||||||||
| R&D Expenses | 247.5 | 141.8 | 85.3 | 81.8 | 64.9 | 37.0 | 11.9 | 3.5 |
| SG&A Expenses | 37.9 | 31.1 | 29.9 | 19.1 | 15.2 | 8.6 | 1.9 | 1.1 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 285.4 | 172.9 | 115.2 | 100.9 | 80.2 | 45.7 | 13.8 | 4.6 |
| Operating Income | ||||||||
| Operating Income | (285.4) | (172.9) | (115.2) | (100.9) | (80.2) | (45.7) | (13.8) | (4.6) |
| Interest Expense | 4.7 | 3.1 | 0.7 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 38.0 | 24.2 | 3.9 | 0.1 | 0.9 | 1.9 | 0 | 0 |
| Profitability | ||||||||
| EBITDA | (247.4) | (148.6) | (111.3) | (100.7) | (79.0) | (45.7) | (68.5) | (0.2) |
| EBIT | (247.4) | (148.7) | (111.3) | (100.8) | (79.2) | (43.7) | (81.7) | (4.6) |
| Income Before Tax | (252.1) | (151.8) | (112.0) | (100.8) | (79.2) | (43.8) | (81.7) | (4.6) |
| Income Tax Expense | 0 | 0 | 0 | 0 | (0.0) | 0 | 0 | 0 |
| Net Income | (252.1) | (151.8) | (112.0) | (100.8) | (79.2) | (43.8) | (81.7) | (4.6) |
| Per Share Data | ||||||||
| EPS (Basic) | -3.75 | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| EPS (Diluted) | -3.75 | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Shares Outstanding | 67.1 | 52.6 | 39.0 | 34.8 | 31.5 | 15.1 | 21.2 | 28.6 |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 340.2 | 234.2 | 249.8 | 150.5 | 187.2 | 64.8 | 76.0 | 0.6 |
| Short-Term Investments | 402.8 | 315.8 | 101.7 | 37.8 | 81.1 | 71.6 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 27.3 | 10.0 | 0 | 0 | 0 | 0 | 1.2 | 0.0 |
| Total Current Assets | 770.4 | 560.0 | 355.2 | 193.6 | 271.3 | 138.0 | 77.1 | 0.6 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 0.8 | 1.0 | 1.3 | 1.5 | 1.8 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 54.8 | 19.3 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
| Other Non-Current Assets | 0 | 0 | 0.1 | 0.4 | 0.2 | 0.1 | 0 | 0 |
| Total Non-Current Assets | 55.5 | 20.3 | 1.4 | 2.0 | 2.0 | 0.1 | 0.0 | 0.0 |
| Total Assets | 825.9 | 580.3 | 356.6 | 195.5 | 273.3 | 138.1 | 77.2 | 0.7 |
| Current Liabilities | ||||||||
| Account Payables | 9.0 | 7.0 | 8.0 | 6.7 | 3.4 | 0.9 | 1.4 | 0.1 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.2 | 1.3 | 10.0 | 0.6 | 0.5 | 1.6 | 0.7 | 0.0 |
| Total Current Liabilities | 39.8 | 19.1 | 19.1 | 25.1 | 13.1 | 9.4 | 2.3 | 0.2 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 35.3 | 25.0 | 9.5 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0.2 | 0.1 | 0.3 | 0 | 0 | 0.0 | 124.7 | 5 |
| Total Non-Current Liabilities | 36.0 | 25.8 | 10.9 | 1.3 | 1.5 | 0.0 | 124.7 | 5 |
| Total Liabilities | 75.8 | 45.0 | 30.0 | 26.4 | 14.6 | 9.4 | 127.1 | 5.2 |
| Stockholders' Equity | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 |
| Retained Earnings | (826.2) | (574.1) | (422.3) | (310.3) | (209.5) | (130.3) | (86.6) | (4.6) |
| Accumulated Other Comprehensive Income | 0.9 | 0.3 | 0.0 | (0.0) | (0.0) | (0.0) | 0 | 0 |
| Total Stockholders' Equity | 750.1 | 535.3 | 326.6 | 169.1 | 258.7 | 128.7 | (49.9) | (4.6) |
| Total Liabilities & Equity | 825.9 | 580.3 | 356.6 | 195.5 | 273.3 | 138.1 | 77.2 | 0.7 |
| Debt Metrics | ||||||||
| Total Debt | 36.5 | 26.3 | 10.9 | 1.5 | 1.8 | 0.1 | 0 | 0 |
| Net Debt | (303.8) | (207.9) | (238.8) | (149.0) | (185.4) | (64.7) | (76.0) | (0.6) |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | (252.1) | (151.8) | (112.0) | (100.8) | (79.2) | (43.8) | (81.7) | (4.6) |
| Depreciation & Amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.1) | 0 | 0 |
| Stock-Based Compensation | 29.7 | 21.5 | 23.2 | 10.1 | 6.0 | 1.8 | 0.1 | 0 |
| Change in Working Capital | 3.0 | (6.7) | (4.5) | 9.7 | 2.1 | 6.5 | 1.1 | 0.2 |
| Other Non-Cash Items | (10.8) | (8.5) | 0.7 | 0.2 | 0.2 | (0.1) | 75.9 | (0.1) |
| Operating Cash Flow | (230.1) | (145.4) | (92.5) | (79.7) | (70.8) | (35.6) | (4.6) | (4.4) |
| Investing Activities | ||||||||
| Capital Expenditure | (1.0) | 0 | 0 | 0 | (0.1) | 0 | (5) | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 |
| Purchases of Investments | (516.0) | (433.1) | (101.4) | (43.6) | (115.0) | (71.5) | 0 | 0 |
| Sales/Maturities of Investments | 407.3 | 209.5 | 37.6 | 85.8 | 105.4 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (0.0) | 0 | (0.0) | 0 |
| Investing Cash Flow | (109.7) | (223.6) | (63.8) | 42.3 | (9.8) | (71.5) | (5) | 0 |
| Financing Activities | ||||||||
| Net Debt Issuance | 10 | 15 | 10 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 12.8 | 2.9 | 4.4 | 0 | 0.6 | 0.5 | (0.5) | 5 |
| Financing Cash Flow | 445.8 | 353.3 | 255.6 | 0.6 | 203.1 | 96.0 | 85.0 | 5 |
| Cash Position | ||||||||
| Net Change in Cash | 106.0 | (15.7) | 99.3 | (36.8) | 122.5 | (11.2) | 75.4 | 0.6 |
| Cash at Beginning | 234.2 | 249.9 | 150.6 | 187.4 | 64.8 | 76 | 0.6 | (0.0) |
| Cash at End | 340.2 | 234.2 | 249.9 | 150.6 | 187.4 | 64.8 | 76 | 0.6 |
| Free Cash Flow | (231.1) | (145.4) | (92.5) | (79.7) | (71.0) | (35.6) | (9.6) | (4.4) |
| Key Metrics | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | (0.2) | 0 | 0 | 0 |
| Operating Income | (285.4) | (172.9) | (115.2) | (100.9) | (80.2) | (45.7) | (13.8) | (4.6) |
| Net Income | (252.1) | (151.8) | (112.0) | (100.8) | (79.2) | (43.8) | (81.7) | (4.6) |
| EPS (Diluted) | -3.75 | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 340.2 | 234.2 | 249.8 | 150.5 | 187.2 | 64.8 | 76.0 | 0.6 |
| Total Assets | 825.9 | 580.3 | 356.6 | 195.5 | 273.3 | 138.1 | 77.2 | 0.7 |
| Total Debt | 36.5 | 26.3 | 10.9 | 1.5 | 1.8 | 0.1 | 0 | 0 |
| Stockholders' Equity | 750.1 | 535.3 | 326.6 | 169.1 | 258.7 | 128.7 | (49.9) | (4.6) |
| Cash Flow | ||||||||
| Operating Cash Flow | (230.1) | (145.4) | (92.5) | (79.7) | (70.8) | (35.6) | (4.6) | (4.4) |
| Capital Expenditure | (1.0) | 0 | 0 | 0 | (0.1) | 0 | (5) | 0 |
| Free Cash Flow | (231.1) | (145.4) | (92.5) | (79.7) | (71.0) | (35.6) | (9.6) | (4.4) |